This site is intended for healthcare professionals
News

Olumiant improved pain, physical function and morning joint stiffness in rheumatoid arthritis in phase III post-hoc analyses. Eli Lilly

Read time: 1 mins
Last updated:20th Dec 2021
Published:3rd Jun 2021
Lilly and Company and Incyte will present data from post-hoc analyses that suggested Olumiant(baricitinib) 4 mg tablet reduced pain and duration of morning joint stiffness, and improved overall physical function at 12 weeks, among patients with moderate to severe rheumatoid arthritis (RA), compared to Humira (adalimumab) and placebo.

These results are being presented at the virtual Annual European Congress of Rheumatology (EULAR), June 2-5, 2021. In a post-hoc analysis of the Phase III RA-BEAM study , patients treated with Olumiant 4 mg saw greater improvements in pain relief and physical function, as well as reduced duration of morning joint stiffness, at 12 weeks compared to Humira and placebo. These differences in pain relief were not influenced by disease activity during treatment. In this analysis, improvements in fatigue with Olumiant 4 mg were greater than with placebo and similar to Humira after 12 weeks of treatment. Safety results were consistent with the established safety profile for Olumiant in patients with RA. Lilly will also present analyses from the prospective Swiss Clinical Quality Management (SCQM) observational cohort, a study that evaluated the effectiveness and persistence of OLumiant compared to other biologics for the treatment of RA.

Condition: Rheumatoid Arthritis
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.